Vonoprazan for treatment of gastroesophageal reflux: pharmacodynamic and pharmacokinetic considerations

References

• Vakil N, van Zanten SV, Kahrilas P, et al. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol. 2006;101(8):1900–1920; quiz 43.
   PubMed Web of Science ®Google Scholar
• de Bortoli N, Nacci A, Savarino E, et al. How many cases of laryngopharyngeal reflux suspected by laryngoscopy are gastroesophageal reflux disease-related? ‎World J. Gastroenterol. 2012 Aug 28;18(32):4363–4370.
   PubMed Web of Science ®Google Scholar
• Richter JE, Penagini R, Tenca A, et al. Barrett’s esophagus: proton pump inhibitors and chemoprevention II. Ann NY Acad Sci. 2011;1232:114–139.
   PubMed Web of Science ®Google Scholar
• El-Serag HB, Sweet S, Winchester CC, et al. Update on the epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut. 2014 Jun;63(6):871–880.
   PubMed Web of Science ®Google Scholar
• Castell DO, Murray JA, Tutuian R, et al. Review article: the pathophysiology of gastro-oesophageal reflux disease - oesophageal manifestations. Aliment Pharmacol Ther. 2004;20(Suppl 9):14–25.
   PubMed Web of Science ®Google Scholar
• Woodland P, Sifrim D. The refluxate: the impact of its magnitude, composition and distribution. Best Pract Res Clin Gastroenterol. 2010;24(6):861–871.
   PubMed Web of Science ®Google Scholar
• Kahrilas PJ, Shaheen NJ, Vaezi MF. American Gastroenterological Association I, Clinical P, Quality Management C. American Gastroenterological Association Institute technical review on the management of gastroesophageal reflux disease. Gastroenterology. 2008;135(4):1392–1413 e1–e5.
   Web of Science ®Google Scholar
• Fuchs KH, Babic B, Breithaupt W, et al. EAES recommendations for the management of gastroesophageal reflux disease. Surg Endosc. 2014;28(6):1753–1773.
   PubMed Web of Science ®Google Scholar
• Bredenoord AJ, Weusten BL, Curvers WL, et al. Determinants of perception of heartburn and regurgitation. Gut. 2006;55(3):313–318.
   PubMed Web of Science ®Google Scholar
• Savarino E, Zentilin P, Frazzoni M, et al. Characteristics of gastro-esophageal reflux episodes in Barrett’s esophagus, erosive esophagitis and healthy volunteers. Neurogastroenterol Motility. 2010;22(10):1061–e280.
   PubMed Web of Science ®Google Scholar
• Koek GH, Sifrim D, Lerut T, et al. Multivariate analysis of the association of acid and duodeno-gastro-oesophageal reflux exposure with the presence of oesophagitis, the severity of oesophagitis and Barrett’s oesophagus. Gut. 2008;57(8):1056–1064.
   PubMed Web of Science ®Google Scholar
• Ashton MG, Holdsworth CD, Ryan FP, et al. Healing of gastric ulcers after one, two, and three months of ranitidine. Br Med J (Clin Res Ed). 1982 Feb 13;284(6314):467–468.
   PubMed Web of Science ®Google Scholar
• Fineberg HV, Pearlman LA. Surgical treatment of peptic ulcer in the United States. Trends before and after the introduction of cimetidine. Lancet. 1981 Jun 13;1(8233):1305–1307.
   PubMed Web of Science ®Google Scholar
• Colin-Jones DG. The role and limitations of H2-receptor antagonist in the treatment of gastro-oesophageal refrux disease. Aliment Pharmacol Ther. 2008;9(Suppl 1):9–14.
   Google Scholar
• Lachman L, Howden CW. Twenty-four-hour intragastric pH: tolerance within 5 days of continuous ranitidine administration. Am J Gastroenterol. 2000;95(1):57–61.
   PubMed Web of Science ®Google Scholar
• Furuta K, Adachi K, Komazawa Y, et al. Tolerance to H2 receptor antagonist correlates well with the decline in efficacy against gastroesophageal reflux in patients with gastroesophageal reflux disease. J Gastroenterol Hepatol. 2006 Oct;21(10):1581–1585.
   PubMed Web of Science ®Google Scholar
• Sandvik AK, Brenna E, Waldum HL. Review article: the pharmacological inhibition of gastric acid secretion–tolerance and rebound. Aliment Pharmacol Ther. 1997;11(6):1013–1018.
   PubMed Web of Science ®Google Scholar
• Sachs G. Proton pump inhibitors and acid-related diseases. Pharmacotherapy. 1997;17(1):22–37.
   PubMed Web of Science ®Google Scholar
• Savarino V, Di Mario F, Scarpignato C. Proton pump inhibitors in GORD An overview of their pharmacology, efficacy and safety. ‎Pharmacol Res. 2009;59(3):135–153.
   PubMed Web of Science ®Google Scholar
• Galmiche JP, Hatlebakk J, Attwood S, et al. Laparoscopic antireflux surgery vs esomeprazole treatment for chronic GERD: the LOTUS randomized clinical trial. JAMA. 2011 May 18;305(19):1969–1977.
   PubMed Web of Science ®Google Scholar
• Chiba N, De Gara CJ, Wilkinson JM, et al. Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis. Gastroenterology. 1997;112(6):1798–1810.
   PubMed Web of Science ®Google Scholar
• Huang JQ, Hunt RH. Pharmacological and pharmacodynamic essentials of H(2)-receptor antagonists and proton pump inhibitors for the practising physician. Best Pract Res Clin Gastroenterol. 2001 Jun;15(3):355–370.
   PubMed Web of Science ®Google Scholar
• Hershcovici T, Fass R. Management of gastroesophageal reflux disease that does not respond well to proton pump inhibitors. Curr Opin Gastroenterol. 2010;26(4):367–378.
   PubMed Web of Science ®Google Scholar
• Fass R, Sifrim D. Management of heartburn not responding to proton pump inhibitors. Gut. 2009;58(2):295–309.
   PubMed Web of Science ®Google Scholar
• Fass R. Proton-pump inhibitor therapy in patients with gastro-oesophageal reflux disease: putative mechanisms of failure. Drugs. 2007;67(11):1521–1530.
   PubMed Web of Science ®Google Scholar
• Sifrim D, Zerbib F. Diagnosis and management of patients with reflux symptoms refractory to proton pump inhibitors. Gut. 2012;61(9):1340–1354.
   PubMed Web of Science ®Google Scholar
• de Bortoli N, Martinucci I, Bellini M, et al. Overlap of functional heartburn and gastroesophageal reflux disease with irritable bowel syndrome. ‎World J. Gastroenterol. 2013 Sep 21;19(35):5787–5797.
   PubMed Web of Science ®Google Scholar
• Savarino V, Savarino E, Parodi A, et al. Functional heartburn and non-erosive reflux disease. Dig Diseases. 2007;25(3):172–174.
   PubMed Web of Science ®Google Scholar
• Jenkins H, Sakurai Y, Nishimura A, et al. Randomised clinical trial: safety, tolerability, pharmacokinetics and pharmacodynamics of repeated doses of TAK-438 (vonoprazan), a novel potassium-competitive acid blocker, in healthy male subjects. Aliment Pharmacol Ther. 2015;41(7):636–648.
   PubMed Web of Science ®Google Scholar
• Sachs G, Shin JM, Hunt R. Novel approaches to inhibition of gastric acid secretion. Curr Gastroenterol Rep. 2010;12(6):437–447.
   PubMedGoogle Scholar
• Kagami T, Sahara S, Ichikawa H, et al. Potent acid inhibition by vonoprazan in comparison with esomeprazole, with reference to CYP2C19 genotype. Aliment Pharmacol Ther. 2016;43(10):1048–1059.
   PubMed Web of Science ®Google Scholar
• Ashida K, Sakurai Y, Hori T, et al. Randomised clinical trial: vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole healing erosive oesophagitis aliment. Pharmacol Ther. 2016 Jan;43(2):240–251.
   Web of Science ®Google Scholar
• Ashida K, Sakurai Y, Nishimura A, et al. Randomised clinical trial: a dose-ranging study of vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the treatment of erosive oesophagitis. Aliment Pharmacol Ther. 2015;42(6):685–695.
   PubMed Web of Science ®Google Scholar
• van Pinxteren B, Sigterman KE, Bonis P, et al. Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease. Cochrane Database Syst Rev. 2010;(11):CD002095. doi:10.1002/14651858.CD002095.pub4
   Google Scholar
• DeVault KR, Castell DO. Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Am J Gastroenterol. 2005; 100(1):190–200.
   PubMed Web of Science ®Google Scholar
• Martinucci I, de Bortoli N, Savarino E, et al. Optimal treatment of laryngopharyngeal reflux disease. Ther Adv Chronic Dis. 2013;4(6):287–301.
   PubMedGoogle Scholar
• Sachs G, Shin JM, Briving C, et al. The pharmacology of the gastric acid pump: the H+,K+ ATPase. Annu Rev Pharmacol Toxicol. 1995;35:277–305.
   PubMed Web of Science ®Google Scholar
• Shin JM, Cho YM, Sachs G. Chemistry of covalent inhibition of the gastric (H+, K+)-ATPase by proton pump inhibitors. J Am Chem Soc. 2004 Jun 30;126(25):7800–7811.
   PubMed Web of Science ®Google Scholar
• Robinson M. Review article: the pharmacodynamics and pharmacokinetics of proton pump inhibitors–overview and clinical implications. Aliment Pharmacol Ther. 2004;20(Suppl 6):1–10.
   PubMed Web of Science ®Google Scholar
• Shin JM, Vagin O, Munson K, et al. Molecular mechanisms in therapy of acid-related diseases. Cell Mol Life Sci. 2008;65(2):264–281.
   PubMed Web of Science ®Google Scholar
• Klotz U, Schwab M, Treiber G. CYP2C19 polymorphism and proton pump inhibitors. Basic Clin Pharmacol Toxicol. 2004;95(1):2–8.
   PubMed Web of Science ®Google Scholar
• Furuta T, Shirai N, Sugimoto M, et al. Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies. Drug Metab Pharmacokinet. 2005;20(3):153–167.
   PubMedGoogle Scholar
• Wedemeyer RS, Blume H. Pharmacokinetic drug interaction profiles of proton pump inhibitors: an update. Drug Safety. 2014;37(4):201–211.
   PubMed Web of Science ®Google Scholar
• Bruley des Varannes S, Coron E, Galmiche JP. Short and long-term PPI treatment for GERD. Do we need more-potent anti-secretory drugs? Best Pract Res Clin Gastroenterol. 2010;24(6):905–921.
   PubMed Web of Science ®Google Scholar
• Reimer C. Safety of long-term PPI therapy. Best Pract Res Clin Gastroenterol. 2013;27(3):443–454.
   PubMed Web of Science ®Google Scholar
• Dutta U, Armstrong D. Novel pharmaceutical approaches to reflux disease. Gastroenterol Clin North Am. 2013;42(1):93–117.
   PubMed Web of Science ®Google Scholar
• de Bortoli N, Martinucci I, Savarino E, et al. Proton pump inhibitor responders who are not confirmed as GERD patients with impedance and pH monitoring: who are they? Neurogastroenterol Motility. 2014;26(1):28–35.
   PubMed Web of Science ®Google Scholar
• Savarino V, Savarino E, Dulbecco P. Proton pump inhibitor failure: why does it occur and how can it be managed? Digestion. 2006;73(4):215–217.
   PubMed Web of Science ®Google Scholar
• de Bortoli N, Martinucci I, Giacchino M, et al. The pharmacokinetics of ilaprazole for gastro-esophageal reflux treatment. Expert Opin Drug Metab Toxicol. 2013;9(10):1361–1369.
   PubMed Web of Science ®Google Scholar
• Munson KB, Sachs G. Inactivation of H+,K+-ATPase by a K+-competitive photoaffinity inhibitor. Biochemistry. 1988 May 31;27(11):3932–3938.
   PubMed Web of Science ®Google Scholar
• Keeling DJ, Laing SM, Senn-Bilfinger J. Interactions of SCH 28080 with the gastric (H+ +K+)-ATPase. Prog Clin Biol Res. 1988;273:255–260.
   PubMedGoogle Scholar
• Parsons ME, Keeling DJ. Novel approaches to the pharmacological blockade of gastric acid secretion. Expert Opin Investig Drugs. 2005 Apr;14(4):411–421.
   PubMed Web of Science ®Google Scholar
• Andersson K, Carlsson E. Potassium-competitive acid blockade: a new therapeutic strategy in acid-related diseases. Pharmacol Ther. 2005;108(3):294–307.
   PubMed Web of Science ®Google Scholar
• Mendlein J, Sachs G. Interaction of a K(+)-competitive inhibitor, a substituted imidazo[1,2a] pyridine, with the phospho- and dephosphoenzyme forms of H+, K(+)-ATPase. J Biol Chem. 1990 Mar 25;265(9):5030–5036.
   PubMed Web of Science ®Google Scholar
• Wurst W, Hartmann M. Current status of acid pump antagonists (reversible PPIs). Yale J Biol Med. 1996;69(3):233–243.
   PubMed Web of Science ®Google Scholar
• Wallmark B, Briving C, Fryklund J, et al. Inhibition of gastric H+,K+-ATPase and acid secretion by SCH 28080, a substituted pyridyl(1,2a)imidazole. J Biol Chem. 1987 Feb 15;262(5):2077–2084.
   PubMed Web of Science ®Google Scholar
• Simon WA, Herrmann M, Klein T, et al. Soraprazan: setting new standards in inhibition of gastric acid secretion. J Pharmacol Exp Ther. 2007 Jun;321(3):866–874.
   PubMed Web of Science ®Google Scholar
• Ene MD, Khan-Daneshmend T, Roberts CJ. A study of the inhibitory effects of SCH 28080 on gastric secretion in man. Br J Pharmacol. 1982;76(3):389–391.
   PubMed Web of Science ®Google Scholar
• Dent J, Kahrilas PJ, Hatlebakk J, et al. A randomized, comparative trial of a potassium-competitive acid blocker (AZD0865) and esomeprazole for the treatment of patients with nonerosive reflux disease. Am J Gastroenterol. 2008 Jan;103(1):20–26.
   PubMed Web of Science ®Google Scholar
• Kim HK, Park SH, Cheung DY, et al. Clinical trial: inhibitory effect of revaprazan on gastric acid secretion in healthy male subjects. J Gastroenterol Hepatol. 2010;25(10):1618–1625.
   PubMed Web of Science ®Google Scholar
• Shin JM, Inatomi N, Munson K, et al. Characterization of a novel potassium-competitive acid blocker of the gastric H,K-ATPase, 1-[5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamin e monofumarate (TAK-438). J Pharmacol Exp Ther. 2011;339(2):412–420.
   PubMed Web of Science ®Google Scholar
• Hori Y, Imanishi A, Matsukawa J, et al. 1-[5-(2-Fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamin e monofumarate (TAK-438), a novel and potent potassium-competitive acid blocker for the treatment of acid-related diseases. J Pharmacol Exp Ther. 2010 Oct;335(1):231–238.
   PubMed Web of Science ®Google Scholar
• Keeling DJ, Taylor AG, Schudt C. The binding of a K+ competitive ligand, 2-methyl,8-(phenylmethoxy)imidazo(1,2-a)pyridine 3-acetonitrile, to the gastric (H+ + K+)-ATPase. J Biol Chem. 1989 Apr 5;264(10):5545–5551.
   PubMed Web of Science ®Google Scholar
• Matsukawa J, Hori Y, Nishida H, et al. A comparative study on the modes of action of TAK-438, a novel potassium-competitive acid blocker, and lansoprazole in primary cultured rabbit gastric glands. Biochem Pharmacol. 2011 May 1;81(9):1145–1151.
   PubMed Web of Science ®Google Scholar
• Scott DR, Munson KB, Marcus EA, et al. The binding selectivity of vonoprazan (TAK-438) to the gastric H+, K+ -ATPase. Aliment Pharmacol Ther. 2015;42(11–12):1315–1326.
   PubMed Web of Science ®Google Scholar
• Hori Y, Matsukawa J, Takeuchi T, et al. A study comparing the antisecretory effect of TAK-438, a novel potassium-competitive acid blocker, with lansoprazole in animals. J Pharmacol Exp Ther. 2011;337(3):797–804.
   PubMed Web of Science ®Google Scholar
• Arikawa Y, Nishida H, Kurasawa O, et al. Discovery of a novel pyrrole derivative 1-[5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamin e fumarate (TAK-438) as a potassium-competitive acid blocker (P-CAB). J Med Chem. 2012 May 10;55(9):4446–4456.
   PubMed Web of Science ®Google Scholar
• Sakurai Y, Nishimura A, Kennedy G, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of single rising TAK-438 (Vonoprazan) doses in healthy male Japanese/non-Japanese subjects. Clin Transl Gastroenterol. 2015;6:e94.
   PubMed Web of Science ®Google Scholar
• Sakurai Y, Mori Y, Okamoto H, et al. Acid-inhibitory effects of vonoprazan 20 mg compared with esomeprazole 20 mg or rabeprazole 10 mg in healthy adult male subjects–a randomised open-label cross-over study. Aliment Pharmacol Ther. 2015;42(6):719–730.
   PubMed Web of Science ®Google Scholar